The MHRA’s Class 4 alert for Ponlimsi denosumab requires healthcare organisations to understand three critical points. First, only the outer carton packaging contains incorrect text—the actual medication and delivery mechanisms are unaffected. Second, both vial and pre-filled syringe labels display correct subcutaneous administration instructions, meaning practitioners have reliable on-product guidance when preparing doses.
Third, the Class 4 classification denotes minimal patient risk, allowing treatment to continue as prescribed without clinical interruption. Providers should verify administration routes using the vial or syringe labels rather than relying solely on carton text, a practice that represents standard medication safety protocol.
Patients currently receiving denosumab therapy should not be alarmed. The alert reflects regulatory vigilance regarding packaging accuracy rather than any compromise to medication quality or safety. Continue treatments as directed by your healthcare provider.
Read the full article on GMJ Newsroom.
Was this article helpful?
